Jeffrey N. Simmons - 07 Aug 2026 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Reporting relationship: PRESIDENT, CEO AND DIRECTOR, Director
Issuer ticker: ELAN
Reported as of: 07 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Aug 2026, 16:15:47 UTC
Prior SEC filing: 28 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons

Key filing fact

Jeffrey N. Simmons filed Form 4 for Elanco Animal Health Inc (ELAN) on 10 Aug 2026.

Key facts

This page summarizes Jeffrey N. Simmons's Form 4 filing for Elanco Animal Health Inc (ELAN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Aug 2026, 16:15.

Change

Previous filing in this sequence was filed on 28 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001479079 Primary reporting owner

Simmons Jeffrey N

Relationship: PRESIDENT, CEO AND DIRECTOR, Director
Address: C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons
Signature date: 10 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELAN transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +128
Change %: +0.51%
Price: $22.12^*
Shares after: 25,012
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 128
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

Footnote F2

Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.